RemeGen's RC118 gets 2 FDA orphan drug designations for gastric, pancreatic cancer

Dec. 13, 2022 7:25 AM ETRemegen Co Ltd. ADR (REGMY), REGMFBy: Ravikash, SA News Editor

FDA Headquarters - White Oak Campus


  • The U.S. Food and Drug Administration (FDA) granted two two orphan drug designations (ODD) to RemeGen's (OTCPK:REGMF) (OTCPK:REGMY) antibody-drug conjugate (ADC) RC118 for injection for gastric cancer (including gastroesophageal junction cancer) and pancreatic cancer.
  • The Chinese company said RC118 is its latest ADC used to

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.